Platelet activating factor-induced mast cell degranulation is inhibited by rupatadine, and to a lower extent by levocetirizine and desoratadine, in a mast cell line (LAD-2) by unknown
ORAL PRESENTATION Open Access
Platelet activating factor-induced mast cell
degranulation is inhibited by rupatadine, and
to a lower extent by levocetirizine and
desoratadine, in a mast cell line (LAD-2)
Joaquim Mullol*, Rosa Muñoz-Cano, I Torres-Atencio, E Ainsua, M Martin, J Sanchez-Lopez, Joan Bartra,
Cesar Picado, Antonio Valero
From 9th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2013)
Leuven, Belgium. 21-23 March 2013
Background
Platelet activating factor (PAF) is a lipid mediator that
appears to be involved in the pathophysiology of several
allergic reactions such as anaphylaxis and potentially
urticaria and allergic rhinitis. The role of rupatadine, a
drug with dual antihistamine and anti-PAF effect, in
mast cell (MC) degranulation is not known. The objec-
tive of this study was to investigate the expression of
PAF receptors and the effect of rupatadine on PAF-
induced MC degranulation compared with other second
generation antihistamines (desloratadine, levocetizine)
and a pure specific PAF inhibitor in a human mast cell
line (LAD-2).
Methodology
MC degranulation was evaluated by the â-hexosaminidase
and histamine release while PAF receptor expression was
evaluated by western blot. After stimulation with PAF in a
dose-response and time course manner, the optimal PAF
conditions to induce LAD-2 degranulation were identified
(10 µM and 30 minutes). The effects of rupatadine, deslor-
atadine, and levocetirizine (from 1µM to 100 µM) on
PAF-induced LAD-2 degranulation were investigated. The
inhibitory effect of CV6209 (specific anti-PAF) at 2 µM
was used as positive control in all experiments.
Results
Protein expression of the PAF receptor was found in
LAD-2 cells. Rupatadine (5 to 10 µM, p<0.005) and levo-
cetirizine (5 µM, p<0.01) but not desloratadine inhibited
PAF-induced â-hexosaminidase release. Rupatadine (1 to
10 µM, p<0.01), levocetirizine (1 to 25 µM, p<0.05), and
desloratadine (10 µM, p<0.05) also inhibited PAF-
induced histamine release.
Conclusions
This study shows that the ant-H1 compunds rupatadine,
and to a lower extent levocetirizine and desloratadine,
have an anti-PAF effect in the mast cell line LAD-2, sug-
gesting that rupatadine could be more effective than other
antihistamine drugs in those allergic disorders where PAF
may act as an important inflammatory mediator.
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